References
- Campanelli D, Melchior M, Fu Y et al. Cloning of cDNA for proteinase 3: a serine protease, antibiotic, and autoantigen from human neutrophils. yExp Med 1990;172:1709–15.
- Dengler R, Munstermann U, al-Batran S et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Bry Haematol 1995;89:250–7.
- Molldrem J, Dermime S, Parker K et al. Targeted T-celltherapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferen-tially lyse human myeloid leukemia cells. Blood 1996;88:2450–7.
- Molldrem Jj, Clave E, Jiang YZ et al. Cytotoxic T lympho-cytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997;90:2529–34.
- Molldrem J, Lee PP, Wang C, Davis MM. High dose anti-gen induces apoptosis of high avidity cytotoxic T lymphocytes (CTL) specific for a myeloid self-peptide. Blood 1998;90:1858.
- Molldremp, Lee PP, Wang C et al. Evidence that specific Tlymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018–23.
- Molldremp, Lee PP, Wang C et al. A PR1-human leukocyteantigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selec-tively lyse chronic myelogenous leukemia. Cancer Res 1999;59:2675–81.
- Braunschweig I, Wang C, Molldrem JJ. Cytotoxic T lym-phocytes (CTL) specific for myeloperoxidase-derived HLA-A2-restricted peptides specifically lyse AML and CML cells. Blood 2000;96: 3291.
- Lu S, Wieder ED, He Z et a/immunity to a novel myeloper-oxidase peptide, proteinase 3 and HA-I minor antigen is present in AML patients that respond to nonablative stem cell transplant. Blood 2001;98:3551.